UC Berkeley letter calls synthetic peptide wellness use unproven amid FDA reclassification

The wire

1. 01A Wellness Letter from the UC Berkeley School of Public Health, summarized in a physician column, says synthetic peptides sold by influencers lack human evidence of safety or effectiveness.
2. 02The column tracks the regulatory shift: 2023 Category 2 placement blocked compounding, and in April the health secretary directed FDA to move peptides to Category 1.
3. 03It reports a July Pharmacy Compounding Advisory Committee vote favoring six peptides for conditions including ulcerative colitis, insomnia and wound healing, and flags angiogenesis and contamination concerns.

From the source

Doctor’s Tip: The peptide craze, an unproven wellness fad

You hear a lot these days about protein and peptides. A previous column addressed protein; today’s is about peptides, based on an article in the current Wellness Letter, published monthly by the UC Berkeley School of Public Health. The first sentence is: “This unproven wellness fad could soon be easier to access, but availability doesn’t equal safety or effectiveness.”